Copy to clipboard 
After attending investor conferences in late 2025 and early 2026, it’s clear the funding environment remains challenging and uneven. Companies in the research, development, and clinical trial phases report greater difficulty securing capital than later-stage companies with commercialized products. This dynamic has played out across funding and M&A activity over the past decade and is already evident in the first quarter of this year.
Below is a brief overview of eight public funding announcements made so far this year. Five involve startups in niche markets, while the remaining three come from established companies pursuing lines of credit and equity investments to support expansion.
Funding for Startups
ATRO Medical closed a €3 million (~USD $3.5 million) financing round. The company has reached a milestone in the clinical evaluation of its latest Artimis Meniscus Prosthesis design. Ongoing studies will further assess the artificial meniscus system in patients experiencing persistent knee pain following meniscus removal. The newly-secured capital will be used to expand clinical evidence generation in ongoing studies; prepare ATRO Medical for the pivotal clinical trial in the United States and Europe; and further optimize manufacturing, regulatory readiness, and clinical operations.
Entirety Biomedical closed a $1.2 million seed financing round to advance its work toward first-in-human clinical trials. Entirety is developing absorbable magnesium implant systems with its patented Curasorb alloy, designed to deliver the strength and handling characteristics of traditional titanium implants, then safely absorb once healing is complete. The company is initially focused on lower extremity and maxillofacial fixation systems.
Entirety completed its first preclinical study in 2024 and is currently conducting three additional preclinical studies. Early data have demonstrated strong osseointegration and will inform the company’s planned first-in-human clinical trial of its headless compression screw system for lower extremity fixation.
The funding round was led by NuFund Venture Group, with participation from Michigan Rise, Union Heritage, Revere Partners, Community Equity Partners, American Society of Plastic Surgeons, and Mass Medical Angels, among others.
MEDIPOST closed on $140 million in funding to accelerate a U.S. Phase III clinical trial of investigational mesenchymal stem cell therapy in the treatment of symptomatic cartilage defects in patients with knee osteoarthritis. The funding, which came from Skylake Equity Partners, Crescendo Equity Partners and other growth equity companies in Korea, will be allocated to expand scientific and operational capabilities, build infrastructure, and scale manufacturing processes.
MEDIPOST leadership noted that umbilical cord blood-derived stem cell therapies bring together biologically young cells, immune tolerance and scalable manufacturing and underscore the innovation and long-term promise of regenerative medicine as a rapidly advancing field.
Nanochon oversubscribed its latest funding round, bringing its total capital raised to date to $11.3 million. The company has developed the Chondrograft implant that allows for immediate weight-bearing and motion in the treatment of lost or damaged cartilage.
Nanochon intends to use the funds to sustain its first in-human clinical study in Canada, deepen research and development efforts, and begin planning for its future pivotal trial. The phase I trial will evaluate safety and efficacy in a prospective, 10-patient, early feasibility study for use in knee cartilage restoration in eligible patients between 22 and 60 years of age having femoral condyle and/or trochlea articular cartilage lesions who have failed conservative therapy, in addition to meeting other criteria.
Orthofuse closed a £2.2 million (~US $3 million) seed round to support the company’s development of 3D-printed implant systems. By leveraging advanced additive manufacturing techniques and novel implant architectures, the company seeks to create solutions designed to reduce the number of surgical steps while ensuring strong fixation.
Orthofuse is focused on improving implant reversibility, allowing surgeons to adjust or reposition hardware without compromising surrounding tissue. This ability would be particularly valuable in complex trauma cases where anatomy can be unpredictable and small adjustments have a major impact.
This investment will enable Orthofuse to advance its technical development, regulatory readiness, and strengthen partnerships as it prepares for early-stage clinical evaluations. The funding round was led by a group of angel investors with participation from ACF investors, Cambridge Angels, and Empirical Ventures.
Funding for Established Companies
Advita Ortho received a $35 million senior secured revolving credit facility from Wingspire Capital. Proceeds of the revolver will be used for general corporate purposes as Advita expands sales of its portfolio of established product lines, including the Equinoxe Shoulder, Vantage Ankle, Alteon Hip, Truliant Knee, Newton balancing technology and GPS navigation, along with distribution of products including the Spartan Hip and Triverse Knee lines.
Advita acquired those assets during the restructuring of Exactech.
CurveBeam AI received Chinese regulatory approval for a $10 million strategic equity investment by Shandong WeiYing Intelligent Medical Technology, a subsidiary of Shandong Weigao Orthopaedic Materials (WEGO Orthopaedics).
The approval covers an initial $4 million tranche, which was invested via a share placement priced at $0.405 per share, while the remaining $6 million will be invested on the achievement of specified commercial and regulatory milestones.
Shandong’s investment is part of a 10-year exclusive commercialization deal that incorporates sales, marketing, distribution, manufacturing, regulatory support and intellectual property agreements for CurveBeam’s weight-bearing CT and proprietary artificial intelligence (AI) technologies in China, Hong Kong, Macau and Taiwan.
OSSIO closed an initial $40 million senior credit facility, with an additional $10 million available to support future growth. The funding came from Horizon Technology Finance and Monroe Capital and will help OSSIO accelerate the company’s portfolio and commercial expansion.
OSSIO is pursuing the development of the first credible replacement for metal implants in the global orthopedic fixation market with OSSIOfiber Intelligent Bone Regeneration Technology. The company conducts product development and manufacturing in Caesarea, Israel, and recently opened its new U.S. headquarters, where commercial operations are based, in Palmetto, Florida.
After attending investor conferences in late 2025 and early 2026, it's clear the funding environment remains challenging and uneven. Companies in the research, development, and clinical trial phases report greater difficulty securing capital than later-stage companies with commercialized products. This dynamic has played out across funding and...
After attending investor conferences in late 2025 and early 2026, it’s clear the funding environment remains challenging and uneven. Companies in the research, development, and clinical trial phases report greater difficulty securing capital than later-stage companies with commercialized products. This dynamic has played out across funding and M&A activity over the past decade and is already evident in the first quarter of this year.
Below is a brief overview of eight public funding announcements made so far this year. Five involve startups in niche markets, while the remaining three come from established companies pursuing lines of credit and equity investments to support expansion.
Funding for Startups
ATRO Medical closed a €3 million (~USD $3.5 million) financing round. The company has reached a milestone in the clinical evaluation of its latest Artimis Meniscus Prosthesis design. Ongoing studies will further assess the artificial meniscus system in patients experiencing persistent knee pain following meniscus removal. The newly-secured capital will be used to expand clinical evidence generation in ongoing studies; prepare ATRO Medical for the pivotal clinical trial in the United States and Europe; and further optimize manufacturing, regulatory readiness, and clinical operations.
Entirety Biomedical closed a $1.2 million seed financing round to advance its work toward first-in-human clinical trials. Entirety is developing absorbable magnesium implant systems with its patented Curasorb alloy, designed to deliver the strength and handling characteristics of traditional titanium implants, then safely absorb once healing is complete. The company is initially focused on lower extremity and maxillofacial fixation systems.
Entirety completed its first preclinical study in 2024 and is currently conducting three additional preclinical studies. Early data have demonstrated strong osseointegration and will inform the company’s planned first-in-human clinical trial of its headless compression screw system for lower extremity fixation.
The funding round was led by NuFund Venture Group, with participation from Michigan Rise, Union Heritage, Revere Partners, Community Equity Partners, American Society of Plastic Surgeons, and Mass Medical Angels, among others.
MEDIPOST closed on $140 million in funding to accelerate a U.S. Phase III clinical trial of investigational mesenchymal stem cell therapy in the treatment of symptomatic cartilage defects in patients with knee osteoarthritis. The funding, which came from Skylake Equity Partners, Crescendo Equity Partners and other growth equity companies in Korea, will be allocated to expand scientific and operational capabilities, build infrastructure, and scale manufacturing processes.
MEDIPOST leadership noted that umbilical cord blood-derived stem cell therapies bring together biologically young cells, immune tolerance and scalable manufacturing and underscore the innovation and long-term promise of regenerative medicine as a rapidly advancing field.
Nanochon oversubscribed its latest funding round, bringing its total capital raised to date to $11.3 million. The company has developed the Chondrograft implant that allows for immediate weight-bearing and motion in the treatment of lost or damaged cartilage.
Nanochon intends to use the funds to sustain its first in-human clinical study in Canada, deepen research and development efforts, and begin planning for its future pivotal trial. The phase I trial will evaluate safety and efficacy in a prospective, 10-patient, early feasibility study for use in knee cartilage restoration in eligible patients between 22 and 60 years of age having femoral condyle and/or trochlea articular cartilage lesions who have failed conservative therapy, in addition to meeting other criteria.
Orthofuse closed a £2.2 million (~US $3 million) seed round to support the company’s development of 3D-printed implant systems. By leveraging advanced additive manufacturing techniques and novel implant architectures, the company seeks to create solutions designed to reduce the number of surgical steps while ensuring strong fixation.
Orthofuse is focused on improving implant reversibility, allowing surgeons to adjust or reposition hardware without compromising surrounding tissue. This ability would be particularly valuable in complex trauma cases where anatomy can be unpredictable and small adjustments have a major impact.
This investment will enable Orthofuse to advance its technical development, regulatory readiness, and strengthen partnerships as it prepares for early-stage clinical evaluations. The funding round was led by a group of angel investors with participation from ACF investors, Cambridge Angels, and Empirical Ventures.
Funding for Established Companies
Advita Ortho received a $35 million senior secured revolving credit facility from Wingspire Capital. Proceeds of the revolver will be used for general corporate purposes as Advita expands sales of its portfolio of established product lines, including the Equinoxe Shoulder, Vantage Ankle, Alteon Hip, Truliant Knee, Newton balancing technology and GPS navigation, along with distribution of products including the Spartan Hip and Triverse Knee lines.
Advita acquired those assets during the restructuring of Exactech.
CurveBeam AI received Chinese regulatory approval for a $10 million strategic equity investment by Shandong WeiYing Intelligent Medical Technology, a subsidiary of Shandong Weigao Orthopaedic Materials (WEGO Orthopaedics).
The approval covers an initial $4 million tranche, which was invested via a share placement priced at $0.405 per share, while the remaining $6 million will be invested on the achievement of specified commercial and regulatory milestones.
Shandong’s investment is part of a 10-year exclusive commercialization deal that incorporates sales, marketing, distribution, manufacturing, regulatory support and intellectual property agreements for CurveBeam’s weight-bearing CT and proprietary artificial intelligence (AI) technologies in China, Hong Kong, Macau and Taiwan.
OSSIO closed an initial $40 million senior credit facility, with an additional $10 million available to support future growth. The funding came from Horizon Technology Finance and Monroe Capital and will help OSSIO accelerate the company’s portfolio and commercial expansion.
OSSIO is pursuing the development of the first credible replacement for metal implants in the global orthopedic fixation market with OSSIOfiber Intelligent Bone Regeneration Technology. The company conducts product development and manufacturing in Caesarea, Israel, and recently opened its new U.S. headquarters, where commercial operations are based, in Palmetto, Florida.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
CL
Carolyn LaWell is ORTHOWORLD's Chief Content Officer. She joined ORTHOWORLD in 2012 to oversee its editorial and industry education. She previously served in editor roles at B2B magazines and newspapers.
